/DISCLAIMER · RESEARCH_COMPOUND

This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.

/FOX04_DRI_10MG
Peptide

FOX04-DRI (10 mg)

Senolytic Peptide

/HALF_LIFE
Prolonged compared to native FOXO4 peptide (due to retro‑inverso design)
/DELIVERY
Subcutaneous injection (after reconstitution in bacteriostatic water or suitable solvent)

/WHAT_IT_IS

FOX04‑DRI (Retro‑Inverso) is a synthetic peptide designed to interfere with the FOXO4/p53 interaction, enabling selective induction of apoptosis in senescent cells to improve tissue function and biological age.

/USAGE

Used in research to remove senescent cells and study aging, tissue regeneration, insulin signaling, and cell cycle control.

/MECHANISM_OF_ACTION

Acts as a cell‑penetrating peptide that disrupts FOXO4 binding to p53, freeing p53 to induce apoptosis in senescent cells.

Reported Benefits

  • +Selective clearance of senescent cells
  • +Improved organ and tissue function
  • +Reduced aging‑related inflammatory signaling
  • +Enhanced insulin sensitivity and metabolic outcomes

Reported Side Effects

  • Limited human safety data
  • Potential off‑target effects in non‑senescent cells

/RESEARCH_NOTES

Demonstrated senolytic effects in preclinical studies by disrupting FOXO4-p53 binding, leading to selective apoptosis in senescent cells. Shows promise in age-related disease models and fibrosis. For research use only.

/REFERENCE

https://pubmed.ncbi.nlm.nih.gov/28340339/
/TRACK_THIS

Browse all 89 in the app.

MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.

Last reviewed: 2026-06-04 · Reference only. Not medical advice. Consult a qualified physician.